Business Acquisition Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Milestone additional payments, contingent amount Milestone Additional Payments, Contingent Amount Milestone Additional Payments, Contingent Amount Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Additional potential grant funding Additional Potential Funding Related To Grant Award Additional Potential Funding Related To Grant Award Number Of Common Stock Warrants Exercised Number Of Common Stock Warrants Exercised Number Of Common Stock Warrants Exercised License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Amended and Restated Two Thousand Fourteen Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan Milestone payment paid in common stock Milestone Payments, Contingent Amount Milestone payments, contingent amount. Statistical Measurement Statistical Measurement [Domain] Incremental borrowing rate Lessee, Operating Lease, Discount Rate Depreciation Depreciation Stock options exercised (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Increase in number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease) Hammock Pharmaceuticals, Inc Hammock Pharmaceuticals, Inc. [Member] Hammock Pharmaceuticals, Inc. [Member] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Milestone payments term Milestone Payments, Term Milestone Payments, Term Additional paid-in capital Additional Paid in Capital, Common Stock Net income (loss) Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Subsequent Event Type Subsequent Event Type [Axis] Equity Component [Domain] Equity Component [Domain] Subsequent Event Type Subsequent Event Type [Domain] Potential annual license maintenance fee, payments in year one Potential Annual License Maintenance Fee, Payments In Year One Potential Annual License Maintenance Fee, Payments In Year One Grant, DARE-PTB1 Grant, DARE-PTB1 [Member] Grant, DARE-PTB1 Leased Properties Lessee, Operating Leases [Text Block] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Related Party Related Party [Domain] Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Plan Name Plan Name [Axis] Business combination shares issued (in usd per share) Business Acquisition, Share Price Supplemental disclosure of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Canceled/forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Cash and cash equivalents Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. Number of operating segments Number of Operating Segments Plan Name Plan Name [Domain] Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Warrant, exercise price, decrease (in usd per share) Warrant, Exercise Price, Decrease Regular purchase, common stock issuable (in shares) (up to) Regular Repurchase, Common Stock Issuable Regular Repurchase, Common Stock Issuable Award Type Award Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Current portion of lease liabilities Operating Lease, Liability, Current Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Related Party Transaction [Domain] Related Party Transaction [Domain] Annual maintenance fee Cost, Maintenance Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Receivables [Abstract] Receivables [Abstract] Canceled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period 2018 At The Market Sales Agreement 2018 At The Market Sales Agreement [Member] 2018 At The Market Sales Agreement Legal Entity Legal Entity [Axis] Total liabilities Liabilities Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Grant, DARE-FRT1 Grant, DARE-FRT1 [Member] Grant, DARE-FRT1 Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Total payment Research and Development Agreement, Commitment, Amount Research and Development Agreement, Commitment, Amount Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock And Warrants Net proceeds from issuance of common stock and warrants. Going Concern Going Concern [Policy Text Block] Going Concern Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Accrued expenses Increase (Decrease) in Accrued Liabilities 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Commission percent Percentage Of Aggregate Commission Percentage of aggregate commission. Common stock issued to microchips capital stock holders (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Warrant exercises, gross Proceeds from Warrant Exercises Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date CRADA CRADA [Member] CRADA Deemed dividend from trigger of down round provision feature Deemed Dividend From Trigger Of Round Down Provision Feature Deemed Dividend From Trigger Of Round Down Provision Feature Business development Business Development Total assets Assets Earnings Per Share [Abstract] Earnings Per Share [Abstract] Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Income Statement Location Income Statement Location [Axis] Antidilutive Securities Antidilutive Securities [Axis] Accrued expenses Accrued Liabilities, Current Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Sales based milestones amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Other cost Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Net Income (Loss) Per Share Earnings Per Share [Text Block] Business acquisition transaction value Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Equity Award Award Type [Domain] Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] Gain on extinguishment of note payable Gain on extinguishment of notes payable and accrued interest Gain (Loss) on Extinguishment of Debt Entity Registrant Name Entity Registrant Name Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Subsequent Events Subsequent Events [Text Block] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Entity Address, City or Town Entity Address, City or Town License agreement termination period due to performance failure License Agreement Termination Period Due To Performance Failure License agreement, termination period due to performance failure. Leases [Abstract] Leases [Abstract] Operating expenses Operating Expenses [Abstract] Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Unamortized stock-based compensation expense Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Asset acquisition, contingent consideration Asset Acquisition, Contingent Consideration Asset Acquisition, Contingent Consideration Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Trading Symbol Trading Symbol Entity File Number Entity File Number Warrants Expiring on April 4, 2026 Warrants Expiring On April Four Two Thousand Twenty Six [Member] Warrants expiring on april four two thousand twenty six. Deferred license revenue Contract with Customer, Liability, Noncurrent Research and development Research and Development Expense Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Accounts payable Increase (Decrease) in Accounts Payable Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Subsequent Events [Abstract] Subsequent Events [Abstract] Total revenue Revenues Working capital Working Capital Increase (Deficit) Working Capital Increase (Deficit) Accounting Standards Update 2017-11 Accounting Standards Update 2017-11 [Member] Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Offering Expenses Offering Expenses Offering Expenses Royalty agreement term Royalty Agreement, Term Royalty Agreement, Term Income (loss) per common share - basic (in usd per share) Earnings Per Share, Basic Loan under paycheck protection program Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Prepaid expenses Prepaid Expense, Current Entity Interactive Data Current Entity Interactive Data Current Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Weighted average amortization period Weighted Average Amortization Period Weighted Average Amortization Period Accumulated deficit Retained Earnings [Member] Common stock Common stock Common Stock [Member] Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Project [Domain] Project [Domain] Contingent consideration, liability Business Combination, Contingent Consideration, Liability Class of Stock [Axis] Class of Stock [Axis] Statement [Table] Statement [Table] Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member] Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. Renewal term of operating lease Lessee, Operating Lease, Renewal Term Document Quarterly Report Document Quarterly Report Current assets Assets, Current [Abstract] Lease liabilities long-term Operating Lease, Liability, Noncurrent Statistical Measurement Statistical Measurement [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Milestone payments Research And Development Milestone Payment Research and development milestone payment. Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Deferred grant funding Deferred Grant Funding Current Deferred Grant Funding Current Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Document Fiscal Year Focus Document Fiscal Year Focus Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Right of use asset Operating Lease, Right-of-Use Asset Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Document Transition Report Document Transition Report Local Phone Number Local Phone Number License fee expense License fee License Fee License Fee Summary of Stock Option Activity for Amended 2014 Plan and Related Information Share-Based Payment Arrangement, Option, Activity [Table Text Block] Legal, accounting and other fees related to purchase agreement Deferred Offering Costs Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Income (loss) from operations Operating Income (Loss) Upfront license fee paid Upfront License Fee Paid Upfront License Fee Paid Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Prepaid expenses Increase (Decrease) in Prepaid Expense Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional paid-in capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Licensing Agreements Licensing Agreements [Member] Document Fiscal Period Focus Document Fiscal Period Focus Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted DARE-LARC1 DARE-LARC1 [Member] DARE-LARC1 Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Expected life in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Common stock, $0.0001 par value; 120,000,000 shares authorized; 84,820,858 and 83,944,119 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively Issues shares Common Stock, Value, Issued Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Issuance of common stock from the exercise of warrants Adjustments to Additional Paid in Capital, Warrant Issued Current liabilities Liabilities, Current [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Initial payment Grants receivable Grants Receivable Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Proceeds from the exercise of stock options Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Income Statement Location Income Statement Location [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Non-cash lease expenses Operating Lease, Cost MBI MBI [Member] MBI Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Catalent and MilanaPharm Catalent and MilanaPharm [Member] Catalent and MilanaPharm Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Entity Current Reporting Status Entity Current Reporting Status Other non-current assets Other Assets, Noncurrent Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Project [Axis] Project [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Stock options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Licensed Product or Process for Vaginal or Urological Use Licensed Product or Process for Vaginal or Urological Use [Member] Licensed Product or Process for Vaginal or Urological Use Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property, Plant and Equipment, Net Cash paid for measurement of operating lease liabilities Operating Lease, Payments Employee Stock Option Stock options Share-Based Payment Arrangement, Option [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Certain clinical and regulatory development milestone payments License Agreement Notice Period Of Termination License Agreement Notice Period Of Termination Square footage of office space Net Rentable Area Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Other income Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Expiration Date Class Of Warrant Or Rights Warrants Expiration Date Class of warrant or rights warrants expiration date. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Initial term of license agreement License Agreement, Initial Term License Agreement, Initial Term License fee revenue License And Collaboration Revenues [Member] License And Collaboration Revenues Class of Warrant or Right Class of Warrant or Right [Axis] Total operating expenses Operating Expenses Maximum Maximum [Member] Percentage of royalty rate Percentage Of Royalty Rate Percentage of royalty rate. Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax 2022 Stock Incentive Plan Two Thousand Twenty Two Stock Incentive Plan [Member] Two Thousand Twenty Two Stock Incentive Plan Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Unamortized costs related to legal, accounting, and other fees Deferred Offering Costs, Unamortized Portion Deferred Offering Costs, Unamortized Portion Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Operating lease, right-of-use asset, statement of financial position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Entity Small Business Entity Small Business Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Measurement Frequency [Domain] Measurement Frequency [Domain] Revenues [Abstract] Revenues [Abstract] Cash paid to stockholders' representative Payments to Stockholders' Representative in Business Combination Payments to Stockholders' Representative in Business Combination Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Grant, ADARE-204 and ADARE-214 Grant, ADARE-204 and ADARE-214 [Member] Grant, ADARE-204 and ADARE-214 Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current License agreement termination periodic discontinued sale of product License Agreement Termination Periodic Discontinued Sale Of Product License Agreement Termination Periodic Discontinued Sale Of Product Other non-current assets Increase Decrease In Other Non Current Assets And Deferred Charges Increase decrease in other non-current assets and deferred charges. Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Purchase Agreement Purchase Agreement [Member] Purchase Agreement Subsequent Event [Line Items] Subsequent Event [Line Items] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Total operating lease liabilities Operating Lease, Liability Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forgiveness of Paycheck Protection Program note payable Forgiveness of Paycheck Protection Program Note Payable Forgiveness of Paycheck Protection Program Note Payable Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Weighted average number of shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Notes payable including accrued interest Notes Payable, Current, Plus Accrued Interest Notes Payable, Current, Plus Accrued Interest Accounts payable Accounts Payable, Current License fee to be paid upon contingency License Fee, To Be Paid Upon Contingency License Fee, To Be Paid Upon Contingency Percentage of rights to inventions by employees under license agreement Percentage Of Rights To Inventions By Employees Under License Agreement Percentage of rights to inventions by employees under license agreement. Other receivables Increase (Decrease) in Other Receivables Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders' equity. Warrants Warrant [Member] Entity Filer Category Entity Filer Category Aggregate net proceeds on sales of shares of common stock Proceeds from Issuance of Common Stock Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stockholders Equity [Table] Stockholders Equity [Table] Stockholders' equity. Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 7) Commitments and Contingencies Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price License fee revenue License [Member] Class of Warrant or Right Class of Warrant or Right [Domain] Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued General and administrative General and Administrative Expense [Member] Total revenue license and collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Cover [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Annual percentage increase in outstanding number of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Stock-Based Compensation Share-Based Payment Arrangement [Text Block] MilanaPharm MilanaPharm [Member] MilanaPharm [Member] Net amount payable Milestone Payments, Contingent Amount Payable, Net Milestone Payments, Contingent Amount Payable, Net Upfront license fee paid Upfront License Fee, Amount Paid Upfront License Fee, Amount Paid Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Warrants Expiring on February 15, 2023 Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Total liabilities and stockholders' equity Liabilities and Equity Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Related Party Related Party [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Less: accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Income (loss) per common share - diluted (in usd per share) Earnings Per Share, Diluted Sale of Stock Sale of Stock [Domain] Offering expenses Payments of Stock Issuance Costs Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Grant Awards Grant Award [Text Block] Grant Award [Text Block] NICHD NICHD [Member] NICHD 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two First commercial sale amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Equity [Abstract] Equity [Abstract] Subsequent Event [Table] Subsequent Event [Table] Other receivables Other Receivables, Net, Current Entity Tax Identification Number Entity Tax Identification Number Options to purchase number of outstanding shares of common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Other Non Current Assets Other Noncurrent Assets [Member] Estimated fair value of warrants recorded in equity Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Lincoln Park Lincoln Park [Member] Lincoln Park Non-cash operating lease cost Non-Cash Lease Expense Non-Cash Lease Expense Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate. Measurement Frequency [Axis] Measurement Frequency [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Strategic Agreements Collaborative Arrangement Disclosure [Text Block] Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Entity Entity [Domain] Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Obligation to purchase common stock Purchase Obligation Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock Sale of Stock [Axis] ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Issuance of common stock from the exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted-average fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value April 2021 At The Market Sales Agreement April 2021 At The Market Sales Agreement [Member] April 2021 At The Market Sales Agreement Shares underlying outstanding warrants (in shares) Class of Warrant or Right, Outstanding Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Potential additional consideration payable Registration Payment Arrangement, Maximum Potential Consideration Research and development Research and Development Expense [Member] Amount awarded for grant Proceeds From Award Of Grant Proceeds From Award Of Grant Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Organon Organon [Member] Organon Payment of additional consideration Payment of Additional Consideration in Business Combination Payment of Additional Consideration in Business Combination